Abstract
IntroductionDopamine dysregulation has been identified as a key modulator of behavioural impairment in neurofibromatosis type 1 (NF1) and a potential therapeutic target. Preclinical research demonstrates reduced dopamine in the brains...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have